{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:17:32Z","timestamp":1789654652739,"version":"4.0.1"},"reference-count":50,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pharmacological management of chronic neuropathic pain (CNP) still represents a major clinical challenge. Collective harnessing of both the scientific evidence base and clinical experience (of clinicians and patients) can play a key role in informing treatment pathways and contribute to the debate on specific treatments (e.g., cannabinoids). A group of expert clinicians (pain specialists and psychiatrists), scientists, and patient representatives convened to assess the relative benefit\u2013safety balance of 12 pharmacological treatments, including orally administered cannabinoids\/cannabis-based medicinal products, for the treatment of CNP in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A decision conference provided the process of creating a multicriteria decision analysis (MCDA) model, in which the group collectively scored the drugs on 17 effect criteria relevant to benefits and safety and then weighted the criteria for their clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>Cannabis-based medicinal products consisting of tetrahydrocannabinol\/cannabidiol (THC\/CBD), in a 1:1 ratio, achieved the highest overall score, 79 (out of 100), followed by CBD dominant at 75, then THC dominant at 72. Duloxetine and the gabapentinoids scored in the 60s, amitriptyline, tramadol, and ibuprofen in the 50s, methadone and oxycodone in the 40s, and morphine and fentanyl in the 30s. Sensitivity analyses showed that even if the pain reduction and quality-of-life scores for THC\/CBD and THC are halved, their benefit\u2013safety balances remain better than those of the noncannabinoid drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation:<\/jats:title>\n                    <jats:p>The benefit\u2013safety profiles for cannabinoids were higher than for other commonly used medications for CNP largely because they contribute more to quality of life and have a more favorable side effect profile. The results also reflect the shortcomings of alternative pharmacological treatments with respect to safety and mitigation of neuropathic pain symptoms. Further high-quality clinical trials and systematic comprehensive capture of clinical experience with cannabinoids is warranted. These results demonstrate once again the complexity and multimodal mechanisms underlying the clinical experience and impact of chronic pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2020.0129","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:28:18Z","timestamp":1616066898000},"page":"482-500","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products"],"prefix":"10.1177","volume":"7","author":[{"given":"David J.","family":"Nutt","sequence":"first","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence D.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Management, Emeritus Professor of Decision Science, London School of Economics and Political Science, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Medical Cannabis Clinicians' Society, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Brander","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Valerie","family":"Curran","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Fayaz","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Finn","sequence":"additional","affiliation":[{"name":"National University of Ireland, Galway, Ireland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Horsted","sequence":"additional","affiliation":[{"name":"Clinic Horsted, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Moltke","sequence":"additional","affiliation":[{"name":"Clinic Horsted, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Sakal","sequence":"additional","affiliation":[{"name":"Drug Science, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haggai","family":"Sharon","sequence":"additional","affiliation":[{"name":"Sagol Brain Institute, Tel-Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoirse E.","family":"O'Sullivan","sequence":"additional","affiliation":[{"name":"CanPharmaConsulting, Nottingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Williams","sequence":"additional","affiliation":[{"name":"AWP Mental Health NHS Trust, Bristol, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Zorn","sequence":"additional","affiliation":[{"name":"European Cannabinoid Therapy Association, Worcester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Schlag","sequence":"additional","affiliation":[{"name":"Drug Science, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1903"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120926677"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000505028"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S159852"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30077-4"},{"key":"e_1_3_4_7_2","unstructured":"Couch D . Left behind: the scale of illegal cannabis use for medicinal intent in the UK2020. https:\/\/www.thecmcuk.org\/left-behind-the-scale-of-illegal-cannabis-use-for-medicinal-intent-in-the-uk (last accessed March10 2020)."},{"key":"e_1_3_4_8_2","unstructured":"United Patients' Alliance (UPA). UPA Patients' Survey 2018. https:\/\/www.upalliance.org\/patient-survey-2018 (last accessed April18 2020)."},{"key":"e_1_3_4_9_2","unstructured":"National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press: Washington DC 2017."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.11607\/ofph.1274"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-015-0089-y"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6358"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001293"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","unstructured":"Fisher E Moore RA Fogarty AE et al. Cannabinoids cannabis and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2020. In Press.","DOI":"10.1097\/j.pain.0000000000001929"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X07304449"},{"key":"e_1_3_4_17_2","first-page":"CD012182","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke M","year":"2018","unstructured":"M\u00fccke M, , Phillips T, , Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018; 3:CD012182.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_18_2","author":"Moore RA","year":"2020","unstructured":"Moore RA, , Fisher E, , Finn DP, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2020 [Epub ahead of print]; DOI: 10.1097\/j.pain.0000000000001941.","journal-title":"Pain"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000775"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1297"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1179544120906461"},{"key":"e_1_3_4_22_2","author":"Mohiuddin M","year":"2020","unstructured":"Mohiuddin M, , Blyth FM, , Degenhardt L, et al. General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. Pain. 2020 [Epub ahead of print]; DOI: 10.1097\/j.pain.0000000000002000.","journal-title":"Pain"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12925"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023600"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00307"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000807"},{"key":"e_1_3_4_27_2","unstructured":"Leong J Salek S Walker S. Benefit-risk assessment of medicines: the development and application of a universal framework for decision-making and effective communication. Wiley-Blackwell: Chichester 2012."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2011.03.001"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12770"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.12.015"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-189"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejor.2009.09.030"},{"key":"e_1_3_4_33_2","unstructured":"Phillips LD. Decision conferencing. In: Edwards W Miles RF von Winterfeldt D eds. Advances in decision analysis: from foundations to applications. Cambridge University Press: Cambridge 2007."},{"key":"e_1_3_4_34_2","unstructured":"European Medicines Agency. Benefit-risk methodology project; Work package 4 report: benefit-risk tools and processes. European Medicines Agency: London 2012."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3958"},{"key":"e_1_3_4_36_2","unstructured":"Phillips LD. Benefit-risk modeling of medicinal products: methods and applications. In: Sashegyi A Felli J Noel R eds. Benefit-risk assessment in pharmaceutical research and development. CRC Press: Boca Raton FL 2014: pp. 59\u201396."},{"key":"e_1_3_4_37_2","unstructured":"LSE\/Catalyze. 2011. Hiview3 www.catalyzeconsulting.com. (last accessed October1 2019)."},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12360"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4255"},{"key":"e_1_3_4_40_2","unstructured":"von Winterfeldt D Edwards W. Decision analysis and behavioral research. Cambridge University Press: Cambridge 1986."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2005.06.009"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3801(02)90004-2"},{"key":"e_1_3_4_43_2","first-page":"349","article-title":"Correlation between neuropathic pain and quality of life","volume":"1","author":"Almeida FC","year":"2018","unstructured":"Almeida FC, , Castilho A, , Cesarino CB, et al. Correlation between neuropathic pain and quality of life. Br J Pain. 2018; 1:349\u2013353.","journal-title":"Br J Pain"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006293"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.06.024"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091414"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00253-6"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","unstructured":"Phillips LD. Best practice for MCDA in healthcare. In: Marsh K Goetghebeur M Thokala P Baltussen R eds. Multi-criteria decision analysis to support healthcare decisions. Springer International Publishing AG New York 2017: pp. 311\u2013329.","DOI":"10.1007\/978-3-319-47540-0_16"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.12.003"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pny176"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnz227"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2020.0129","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2020.0129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2020.0129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:21Z","timestamp":1777385481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2020.0129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8,1]]}},"alternative-id":["10.1089\/can.2020.0129"],"URL":"https:\/\/doi.org\/10.1089\/can.2020.0129","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}